Emapalumab Therapy for Hemophagocytic Lymphohistiocytosis Prior to Reduced-Intensity Transplantation Improves Chimerism

To understand the potential impact of emapalumab on post-HSCT outcomes investigators conducted a retrospective study of pediatric patients with hemophagocytic lymphohistiocytosis (HLH) receiving a first reduced intensity conditioning-HSCT at their institution between 2014 and 2022 after treatment for HLH, with or without this agent.